Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia

PI3Kδ inhibitors such as idelalisib are providing improved therapeutic options for the treatment of chronic lymphocytic leukaemia (CLL). However under certain conditions, inhibition of a single PI3K isoform can be compensated by the other PI3K isoforms, therefore PI3K inhibitors which target multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Blunt, Matthew D., Steele, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588368/
https://www.ncbi.nlm.nih.gov/pubmed/26500849
http://dx.doi.org/10.1016/j.lrr.2015.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588368/
https://www.ncbi.nlm.nih.gov/pubmed/26500849
http://dx.doi.org/10.1016/j.lrr.2015.09.001

Ejemplares similares